Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

Blood (2019) 134 (Supplement_1): 2843.

https://doi.org/10.1182/blood-2019-126661

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

Joshua F Ransom, PhD, Aaron Galaznik, MDMBA, Emelly Rusli, Bruno Lempernesse, MS, Marc Berger, MD

Blood (2019) 134 (Supplement_1): 4895.

https://doi.org/10.1182/blood-2019-129086

Published: 2019

Journal Articles

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Siliang Chen, Zheyuan Qin, Stephen Liang, MD

Blood (2018) 132 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2018-99-118481

Published: 2018

Journal Articles

Adaptive NK Cells Are Expanded By NKG2C-Agonist Antibodies and Retain Their Cytotoxic and Secretory Properties

Aimee Merino, MD PhD, Phillip Dougherty, BS, Bin Zhang, PhD, J.P. Houchins, PhD, Jeffrey S. Miller, MD, Frank Cichocki, PhD

Blood (2018) 132 (Supplement 1): 3695.

https://doi.org/10.1182/blood-2018-99-113669

Published: 2018

Journal Articles

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Tong-Yoon Kim, MD, Sung-Eun Lee, Soo-Hyun Kim, Soo-Young Choi, Eun-Jung Jang, Dong-Wook Kim, MD PhD

Blood (2016) 128 (22): 1900.

https://doi.org/10.1182/blood.V128.22.1900.1900

Published: 2016

Journal Articles

High Incidence of Secondary Malignancies after Reduced Intensity Allo-SCT: Results of a Single-Center Study with Extended Follow-up

Jeremy Delage, Stephane Vigouroux, Reza Tabrizi, Catherine Mohr, Pascal Turlure, MD, Noel Milpied

Blood (2015) 126 (23): 4353.

https://doi.org/10.1182/blood.V126.23.4353.4353

Published: 2015

Journal Articles

Clinicopathologic Features and Survival Outcomes of Secondary Mantle Cell Lymphoma after Primary Solid Malignancy

Raji Shameem, MD, Muhammad Saad Hamid, MD, Nasheed Mohammad Hossain, MD, Jeffrey Mufson, MD, Patricia L. Kropf, MD

Blood (2015) 126 (23): 2652.

https://doi.org/10.1182/blood.V126.23.2652.2652

Published: 2015

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Journal Articles

TK-Cells Safety and Efficacy in Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Clinical and Molecular Assessment in 128 Treated Patients.

Maria Teresa Lupo-Stanghellini, MD, Giacomo Oliveira, MSc, Raffaella Greco, MD, Luca Vago, MD PhD, Attilio Bondanza, MD, PhD, Fabio Ciceri, MD, Claudio Bordignon, MD, Chiara Bonini, MD

Blood (2012) 120 (21): 3061.

https://doi.org/10.1182/blood.V120.21.3061.3061

Published: 2012

Journal Articles

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

*Catriona A. Hayes, MD, *Paul Dowling, PhD, Joseph Negri, Michael Henry, Leutz Buon, Jana Jakubikova, PhD, Jake E Delmore, Douglas W. McMillin, PhD, Steffen Klippel, PhD, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Panisinee Lawasut, MD, MSc, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, *Peter O Gorman, MD, PhD, *Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 1820.

https://doi.org/10.1182/blood.V118.21.1820.1820

Published: 2011

Journal Articles

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Dagmar Hess, MD, Nicole Hagner, MD, Sally Clive, MD, Hans Gelderblom, MD, PhD, Eva Rossmann, MD, PhD, Neeraj Agarwal, MD, Maria Grazia Porro, PhD, Thomas Hengelage, PhD, Annie St-Pierre, PhD, Lucien Gazi, PhD, Jason Li, PhD, Margaret M. Woo, PharmD, Sunil Sharma, MD

Blood (2011) 118 (21): 5007.

https://doi.org/10.1182/blood.V118.21.5007.5007

Published: 2011

Journal Articles

Prognostic Significance of Immune Thrombocytopenic Purpura In Patients with Malignancy.

Hyojeong Kim, Hyeon-Seok Eom, Sun-Young Kong, MD, PhD, Sook Ryun Park, Sun Young Kim, Jungsil Ro, Sang-Yoon Park

Blood (2010) 116 (21): 1428.

https://doi.org/10.1182/blood.V116.21.1428.1428

Published: 2010

Journal Articles

Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.

Mark S. Kaminski, MD, Melissa Tuck, MS, Judith Estes, BSN, MSN, Arne Kolstad, MD, PhD, Charles Warren Ross, MD, Denise Regan, BS, Thierry Horner, PhD, Vanessa C. Williams, MS, Tina Vleisides, DC, Richard L. Wahl, MD

Blood (2009) 114 (22): 3759.

https://doi.org/10.1182/blood.V114.22.3759.3759

Published: 2009

Journal Articles

Low Molecular Weight Heparin in Patients with Cancer: A New Option

Giorgio Corinaldesi, MD, PhD, Christian Corinaldesi

Blood (2008) 112 (11): 4058.

https://doi.org/10.1182/blood.V112.11.4058.4058

Published: 2008

Journal Articles

Extreme Leukocytosis in the 21st Century Is Often Iatrogenic

Zachary P. Hugo, MD, Michael C. Perry, MD, David P. Steensma, MD, FACP

Blood (2008) 112 (11): 5401.

https://doi.org/10.1182/blood.V112.11.5401.5401

Published: 2008

Journal Articles

Non Hodgkin Lymphomas Showing Microsatellite Instability (MSI-H NHL) Are Characterized by Both Specific Biological and Clinical Features.

Claire Borie, Martine Raphael, Olivier Buhard, Alex Duval

Blood (2006) 108 (11): 4754.

https://doi.org/10.1182/blood.V108.11.4754.4754

Published: 2006

Journal Articles

Expression of Protein Z (PZ) and Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Human Malignant Tissues.

Ewa Sierko, MD, Marek Wojtukiewicz, MD, Piotr Tokajuk, MD, Lech Zimnoch, MD, Rodryg Ramlau, MD, Walter Kisiel, PhD, George J. Broze, PhD

Blood (2005) 106 (11): 1028.

https://doi.org/10.1182/blood.V106.11.1028.1028

Published: 2005

Journal Articles

Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues.

Ewa Sierko, M.D., Piotr Tokajuk, M.D., Rodryg Ramlau, M.D., Lech Zimnoch, M.D., Walter Kisiel, Ph.D., Marek Wojtukiewicz, M.D.

Blood (2004) 104 (11): 3958.

https://doi.org/10.1182/blood.V104.11.3958.3958

Published: 2004

Journal Articles

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Emilio Iannitto, MD, Stefano De Cantis, PhD, Viviana Minardi, MD, Vincenzo Callea, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Emanuele Ammatuna, MD, Caterina Stelitano, MD, Claudio Tripodo, MD, Achille Ambrosetti, MD, Giovanni Pizzolo, MD, Ada Florena, MD, Vito Franco, MD, Ada Florena, MD

Blood (2004) 104 (11): 4536.

https://doi.org/10.1182/blood.V104.11.4536.4536

Published: 2004

NARROW

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

A Twenty Years Epidemiology Study of 2 nd Hematological Malignancies Post to the Initial Tumor Treatment: Report from Southern China Single Cancer Group

Adaptive NK Cells Are Expanded By NKG2C-Agonist Antibodies and Retain Their Cytotoxic and Secretory Properties

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

High Incidence of Secondary Malignancies after Reduced Intensity Allo-SCT: Results of a Single-Center Study with Extended Follow-up

Clinicopathologic Features and Survival Outcomes of Secondary Mantle Cell Lymphoma after Primary Solid Malignancy

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

TK-Cells Safety and Efficacy in Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Clinical and Molecular Assessment in 128 Treated Patients.

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Prognostic Significance of Immune Thrombocytopenic Purpura In Patients with Malignancy.

Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.

Low Molecular Weight Heparin in Patients with Cancer: A New Option

Extreme Leukocytosis in the 21st Century Is Often Iatrogenic

Non Hodgkin Lymphomas Showing Microsatellite Instability (MSI-H NHL) Are Characterized by Both Specific Biological and Clinical Features.

Expression of Protein Z (PZ) and Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Human Malignant Tissues.

Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues.

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only